Gut microbiota and intestinal mucosal immune system (Gut-Immune Axis)

The gut microbiota and intestinal mucosal immune system constitute a dynamic and reciprocal relationship that is fundamental to host homeostasis and immune development (Nature Reviews Immunology, 2013). The intestinal mucosa serves as the primary interface where the host's immune system encounters a vast array of commensal microorganisms, requiring a delicate balance between tolerance to beneficial microbes and defense against pathogens (PubMed, PMID: 28123061). This interaction is largely mediated by microbial-derived metabolites, such as short-chain fatty acids (SCFAs), which influence the differentiation of regulatory T cells (Tregs) and the production of secretory IgA (Cell, 2013). Disruptions in this crosstalk, known as dysbiosis, are strongly associated with the pathogenesis of inflammatory bowel disease (IBD), allergies, and metabolic disorders like obesity (NIH, 2021). Therapeutic interventions targeting this axis include probiotics, prebiotics, and fecal microbiota transplantation (FMT), which aim to restore microbial diversity and modulate mucosal immune signaling (Lancet Gastroenterology & Hepatology, 2019). Understanding this system is crucial for developing precision medicine approaches that leverage the microbiome to treat systemic and localized inflammatory conditions.

Other names

Gut-immune axisMicrobiota-immune crosstalkIntestinal microbiome-immune system interactionHost-microbe interface

Modulation of the gut-immune axis occurs through the production of microbial metabolites such as short-chain fatty acids (SCFAs), activation of pattern recognition receptors (PRRs) like Toll-like receptors (TLRs), and the induction of specific immune cell subsets including regulatory T cells (Tregs) and Th17 cells (Nature, 2017).